Physician profile
Claudia Suarez
NPI 1508969015
$13,410.91
in general payments reported to CMS, 2019-2025
29 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $500 · 2021: $242 · 2022: $375 · 2023: $332 · 2024: $15.45 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,398.75 | 2019-2020 | |
| Duchesnay USA Incorporated | $1,668.57 | 2019 | |
| Abbvie INC. | $518.20 | 2019-2025 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $330.71 | 2019-2025 | |
| Avion Pharmaceuticals | $209.74 | 2019-2023 | Balcoltra |
| Lupin INC. | $185.25 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $178.80 | 2019-2025 | |
| Hologic Sales and Service, LLC | $155.01 | 2020-2023 | Myosure Tissue Removal Device, Novasure, Omni Hysteroscope |
| Medtronic, INC. | $143.72 | 2022-2023 | V-Loc 180 |
| Astellas Pharma US INC | $86.08 | 2023-2025 | Veozah |
| Organon LLC | $54.10 | 2021-2025 | Nexplanon |
| Evofem Biosciences, INC. | $54.00 | 2022-2023 | Phexxi |
| Smith+Nephew, INC. | $46.82 | 2023-2025 | Pico, Pico 14 |
| Vertical Pharmaceuticals, LLC | $45.47 | 2019-2020 | |
| Allergan, INC. | $43.57 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $38.11 | 2019-2020 | |
| Medtronic Vascular, INC. | $35.80 | 2019 | |
| Mayne Pharma Commercial LLC | $24.41 | 2025 | |
| Exeltis, USA INC. | $24.20 | 2019-2023 | Slynd |
| Coopersurgical, INC. | $24.14 | 2021 | |
| Sumitomo Pharma America, INC. | $20.06 | 2023 | Myfembree |
| Sage Therapeutics, LLC | $18.26 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $18.04 | 2025 | Bridion |
| Caldera Medical, INC | $17.41 | 2022 | |
| Axonics, INC. | $16.65 | 2022 | |
| Shield Therapeutics INC | $15.45 | 2024 | |
| Acessa Health INC. | $13.86 | 2019 | |
| Ethicon US, LLC | $13.20 | 2020 | |
| Scynexis, INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.